JPH09510877A - マラリアペプチド - Google Patents
マラリアペプチドInfo
- Publication number
- JPH09510877A JPH09510877A JP7525507A JP52550795A JPH09510877A JP H09510877 A JPH09510877 A JP H09510877A JP 7525507 A JP7525507 A JP 7525507A JP 52550795 A JP52550795 A JP 52550795A JP H09510877 A JPH09510877 A JP H09510877A
- Authority
- JP
- Japan
- Prior art keywords
- hla
- peptides
- peptide
- ctl
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 94
- 201000004792 malaria Diseases 0.000 title claims abstract description 20
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims abstract description 65
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 55
- 239000000427 antigen Substances 0.000 claims abstract description 27
- 108091007433 antigens Proteins 0.000 claims abstract description 27
- 102000036639 antigens Human genes 0.000 claims abstract description 27
- 230000004044 response Effects 0.000 claims abstract description 17
- 238000000034 method Methods 0.000 claims abstract description 16
- 230000003053 immunization Effects 0.000 claims abstract description 9
- 229960005486 vaccine Drugs 0.000 claims abstract description 9
- 238000002649 immunization Methods 0.000 claims abstract description 8
- 230000001939 inductive effect Effects 0.000 claims abstract description 8
- 210000004698 lymphocyte Anatomy 0.000 claims abstract description 8
- 108091034117 Oligonucleotide Proteins 0.000 claims abstract description 7
- 244000005700 microbiome Species 0.000 claims abstract description 6
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims abstract description 3
- 210000000265 leukocyte Anatomy 0.000 claims abstract 2
- 241000223960 Plasmodium falciparum Species 0.000 claims description 15
- 108010091938 HLA-B7 Antigen Proteins 0.000 claims description 11
- 238000001727 in vivo Methods 0.000 claims description 11
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- 108010002350 Interleukin-2 Proteins 0.000 claims description 6
- 102000000588 Interleukin-2 Human genes 0.000 claims description 6
- 108010002586 Interleukin-7 Proteins 0.000 claims description 4
- 102000000704 Interleukin-7 Human genes 0.000 claims description 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 4
- 101710104031 Thrombospondin-related anonymous protein Proteins 0.000 claims description 4
- 229940100994 interleukin-7 Drugs 0.000 claims description 4
- 210000004185 liver Anatomy 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108700028369 Alleles Proteins 0.000 claims description 3
- 238000011534 incubation Methods 0.000 claims description 3
- 150000002632 lipids Chemical class 0.000 claims description 3
- 101710145634 Antigen 1 Proteins 0.000 claims description 2
- 125000000539 amino acid group Chemical group 0.000 claims description 2
- 210000003046 sporozoite Anatomy 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 108010002616 Interleukin-5 Proteins 0.000 claims 1
- 108010090127 Periplasmic Proteins Proteins 0.000 claims 1
- 108060003552 hemocyanin Proteins 0.000 claims 1
- 102000025850 HLA-A2 Antigen Human genes 0.000 abstract description 17
- 108010074032 HLA-A2 Antigen Proteins 0.000 abstract description 17
- 108010039075 HLA-B8 Antigen Proteins 0.000 abstract description 10
- 108010013698 HLA-B17 antigen Proteins 0.000 abstract description 9
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 20
- 238000003556 assay Methods 0.000 description 11
- 208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 description 10
- 230000009089 cytolysis Effects 0.000 description 10
- 229940024606 amino acid Drugs 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 6
- 230000006698 induction Effects 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 244000045947 parasite Species 0.000 description 5
- 108010043021 HLA-B58 Proteins 0.000 description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 208000002476 Falciparum Malaria Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 201000011336 Plasmodium falciparum malaria Diseases 0.000 description 3
- 102000003790 Thrombin receptors Human genes 0.000 description 3
- 108090000166 Thrombin receptors Proteins 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
- 229960000310 isoleucine Drugs 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 238000000159 protein binding assay Methods 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 239000004474 valine Substances 0.000 description 3
- 108010004141 HLA-B35 Antigen Proteins 0.000 description 2
- 108010033369 HLA-B57 antigen Proteins 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 208000030852 Parasitic disease Diseases 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 125000001165 hydrophobic group Chemical group 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 102100032303 26S proteasome non-ATPase regulatory subunit 2 Human genes 0.000 description 1
- 229920003026 Acene Polymers 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- -1 HLA acenes Chemical class 0.000 description 1
- 102000011786 HLA-A Antigens Human genes 0.000 description 1
- 108010075704 HLA-A Antigens Proteins 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 101000590272 Homo sapiens 26S proteasome non-ATPase regulatory subunit 2 Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical group NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010035500 Plasmodium falciparum infection Diseases 0.000 description 1
- 241001600434 Plectroglyphidodon lacrymatus Species 0.000 description 1
- 102400000745 Potential peptide Human genes 0.000 description 1
- 101800001357 Potential peptide Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 229940022005 RNA vaccine Drugs 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
- 102100022919 Tartrate-resistant acid phosphatase type 5 Human genes 0.000 description 1
- 101710164277 Tartrate-resistant acid phosphatase type 5 Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108060008245 Thrombospondin Proteins 0.000 description 1
- 102000002938 Thrombospondin Human genes 0.000 description 1
- 241000251221 Triakidae Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- MULRMTLVICSWMO-JCKUYFFHSA-N [(z)-octadec-9-enyl] (2s)-2-acetamido-5-amino-5-oxopentanoate Chemical compound CCCCCCCC\C=C/CCCCCCCCOC(=O)[C@@H](NC(C)=O)CCC(N)=O MULRMTLVICSWMO-JCKUYFFHSA-N 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- JIUQEWIVUUPBBX-GTIIZKDVSA-N hiv31 Chemical compound C([C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(N[C@@H](CCC(=O)NCCCCCNC(=O)CC[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N1)[C@@H](C)CC)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CCC(O)=O)[C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]1C(N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)NCCCCCNC(=O)CC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(N)=O)=O)=O)[C@@H](C)CC)C1=CN=CN1 JIUQEWIVUUPBBX-GTIIZKDVSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000002794 lymphocyte assay Methods 0.000 description 1
- 229940124735 malaria vaccine Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 241000737598 recombinant Hepatitis B virus Species 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
- C07K14/445—Plasmodium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9406492.0 | 1994-03-31 | ||
GB9406492A GB9406492D0 (en) | 1994-03-31 | 1994-03-31 | Malaria peptides |
PCT/GB1995/000737 WO1995026982A2 (en) | 1994-03-31 | 1995-03-30 | Malaria peptides |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005124999A Division JP2006180865A (ja) | 1994-03-31 | 2005-04-22 | マラリアペプチド |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH09510877A true JPH09510877A (ja) | 1997-11-04 |
Family
ID=10752882
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP7525507A Ceased JPH09510877A (ja) | 1994-03-31 | 1995-03-31 | マラリアペプチド |
JP2005124999A Pending JP2006180865A (ja) | 1994-03-31 | 2005-04-22 | マラリアペプチド |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005124999A Pending JP2006180865A (ja) | 1994-03-31 | 2005-04-22 | マラリアペプチド |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0753009B1 (de) |
JP (2) | JPH09510877A (de) |
AT (1) | ATE201215T1 (de) |
DE (1) | DE69520943T2 (de) |
GB (1) | GB9406492D0 (de) |
WO (1) | WO1995026982A2 (de) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013512866A (ja) * | 2009-12-05 | 2013-04-18 | ルプレヒト−カールス−ウニヴェルジテート ハイデルベルク | アピコンプレクサFerlin、Ferlin様タンパク質、及び他のC2ドメイン含有タンパク質に基づくマラリアワクチン |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9266930B1 (en) | 1993-03-05 | 2016-02-23 | Epimmune Inc. | Inducing cellular immune responses to Plasmodium falciparum using peptide and nucleic acid compositions |
US6413517B1 (en) * | 1997-01-23 | 2002-07-02 | Epimmune, Inc. | Identification of broadly reactive DR restricted epitopes |
US7067117B1 (en) | 1997-09-11 | 2006-06-27 | Cambridge University Technical Services, Ltd. | Compounds and methods to inhibit or augment an inflammatory response |
US6989435B2 (en) | 1997-09-11 | 2006-01-24 | Cambridge University Technical Services Ltd. | Compounds and methods to inhibit or augment an inflammatory response |
US7238711B1 (en) | 1999-03-17 | 2007-07-03 | Cambridge University Technical Services Ltd. | Compounds and methods to inhibit or augment an inflammatory response |
EP1404877B1 (de) | 2001-07-02 | 2010-01-06 | Bioincept, LLC. | Assays für den präimplantationsfaktor und präimplantationsfaktorpeptide |
US8222211B2 (en) | 2001-07-02 | 2012-07-17 | Bioincept, Llc | Methods of administering PIF agonist peptides and uses thereof |
US7723289B2 (en) * | 2003-10-22 | 2010-05-25 | Bioincept, Llc | PIF tetrapeptides |
US7723290B2 (en) * | 2004-10-22 | 2010-05-25 | Bioincept, Llc | Compositions and methods for modulating the immune system |
US9333249B2 (en) | 2006-02-09 | 2016-05-10 | Educational Foundation Jichi Medical University | Recombinant baculovirus vaccine |
TWI477602B (zh) | 2006-02-09 | 2015-03-21 | Educational Foundation Jichi Medical Univ | Novel viral vector |
JP6166858B2 (ja) | 2011-03-02 | 2017-07-19 | バイオインセプト、エルエルシー | 細胞内損傷の治療のための組成物および方法 |
US9169304B2 (en) | 2012-05-01 | 2015-10-27 | Pfenex Inc. | Process for purifying recombinant Plasmodium falciparum circumsporozoite protein |
EP3341739A4 (de) | 2015-08-28 | 2019-07-10 | BioIncept LLC | Mutierte peptide und verfahren zur behandlung von subjekten damit |
WO2017040186A1 (en) | 2015-08-28 | 2017-03-09 | Bioincept, Llc | Compositions and methods for the treatment of neurodamage |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5028425A (en) * | 1988-07-07 | 1991-07-02 | The United States Of America As Represented By The Department Of Health And Human Services | Synthetic vaccine against P. falciparum malaria |
GB8819209D0 (en) * | 1988-08-12 | 1988-09-14 | Research Corp Ltd | Polypeptide & dna encoding same |
US5972351A (en) * | 1992-04-03 | 1999-10-26 | Isis Innovation Limited | Plasmodium falciparum MHC class I-restricted CTL epitopes derived from pre-erythrocytic stage antigens |
-
1994
- 1994-03-31 GB GB9406492A patent/GB9406492D0/en active Pending
-
1995
- 1995-03-30 DE DE69520943T patent/DE69520943T2/de not_active Expired - Fee Related
- 1995-03-30 WO PCT/GB1995/000737 patent/WO1995026982A2/en active IP Right Grant
- 1995-03-30 AT AT95913269T patent/ATE201215T1/de not_active IP Right Cessation
- 1995-03-30 EP EP95913269A patent/EP0753009B1/de not_active Expired - Lifetime
- 1995-03-31 JP JP7525507A patent/JPH09510877A/ja not_active Ceased
-
2005
- 2005-04-22 JP JP2005124999A patent/JP2006180865A/ja active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013512866A (ja) * | 2009-12-05 | 2013-04-18 | ルプレヒト−カールス−ウニヴェルジテート ハイデルベルク | アピコンプレクサFerlin、Ferlin様タンパク質、及び他のC2ドメイン含有タンパク質に基づくマラリアワクチン |
Also Published As
Publication number | Publication date |
---|---|
DE69520943D1 (de) | 2001-06-21 |
JP2006180865A (ja) | 2006-07-13 |
DE69520943T2 (de) | 2001-11-08 |
EP0753009A1 (de) | 1997-01-15 |
EP0753009B1 (de) | 2001-05-16 |
WO1995026982A2 (en) | 1995-10-12 |
WO1995026982A3 (en) | 1996-02-15 |
ATE201215T1 (de) | 2001-06-15 |
GB9406492D0 (en) | 1994-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2006180865A (ja) | マラリアペプチド | |
JP6943545B2 (ja) | 腫瘍特異的なネオ抗原を同定する組成物および方法 | |
Widmann et al. | T helper epitopes enhance the cytotoxic response of mice immunized with MHC class I-restricted malaria peptides | |
KR100235849B1 (ko) | HIV에 대한 면역응답을 유도할 수 있는 펩티드 및 그 펩티드를 함유하는 항 AIDS 예방, 치료제(Peptides Capable of Inducing Immune Response to HIV and Anti-AIDS Agent for Preventing and Curing AIDS) | |
JP4272201B2 (ja) | Hla結合性ペプチド及びその用途 | |
TWI517859B (zh) | 癌抗原輔助肽 | |
JP3926839B2 (ja) | 万能dr−結合性ペプチドを用いる免疫応答の改変 | |
JP2004154138A (ja) | 免疫原性ペプチド | |
JP3650110B2 (ja) | B型肝炎ウイルスに対する細胞毒性tリンパ球応答を誘発するためのペプチド | |
JPH08507525A (ja) | Hla−a2.1結合ペプチドおよびそれらの使用 | |
JP3536179B2 (ja) | Hla−a2分子と複合する腫瘍拒絶抗原前駆体由来の単離ペプチド | |
JP2002507397A (ja) | Hla結合ペプチド及びその使用 | |
IL189389A (en) | Tumor-repellent antigenic peptides that are a derivative of glyphicane-3 (3GPC) that are effective for use in patients who are classified as 2 A-HLA-positive and pharmaceutical preparations that contain them | |
JP2002515868A (ja) | Hla結合ペプチド及びその使用 | |
JP2007501602A5 (de) | ||
CN106573960A (zh) | 用于针对乙型肝炎病毒感染的治疗性接种的合成长肽(slp) | |
JPH03503166A (ja) | 抗hiv応答を喚起する合成抗原 | |
JPH08507080A (ja) | B型肝炎のウイルスに対する細胞障害性tリンパ球の応答を誘発するペプチド | |
Franke et al. | A subdominant CD8+ cytotoxic T lymphocyte (CTL) epitope from the Plasmodium yoelii circumsporozoite protein induces CTLs that eliminate infected hepatocytes from culture | |
JPH10503493A (ja) | Hla 結合性ペプチド及びそれらの使用 | |
ES2498371T3 (es) | Antígenos de Plasmodium falciparum y procedimientos de uso | |
WO2005068632A1 (ja) | HLA−A2402拘束性Ep−CAM特異的CTLが認識するエピトープ・ペプチド及びその用途 | |
JP2008509072A (ja) | 改良型ワクチン用のポリペプチド‐アジュバント複合体 | |
Karpenko et al. | Results of phase I clinical trials of a combined vaccine against HIV-1 based on synthetic polyepitope immunogens | |
Becker | Need for cellular and humoral immune responses in bovines to ensure protection from foot-and-mouth disease virus (FMDV)—a point of view |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A72 | Notification of change in name of applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A721 Effective date: 20040706 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20041026 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20050125 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20050328 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050422 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060131 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20060619 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20061107 |